July 1st 2025
Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.
June 30th 2025
Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.
June 24th 2025
225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.
June 23rd 2025
Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.
June 18th 2025
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
FDA Approves PET Imaging Agent for Prostate Cancer
The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.
New Partnership May Expand Use of Prostate Cancer AI Technology Platform
Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.
Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC
Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
“Even after doing 10,000 of these operations, we are tweaking [the hood technique]…to make things better,” according to Ash Tewari, MD, MBBS, MCh, FRCS.
Darolutamide/ADT Yields Consistent Outcomes Across HSPC Age Subgroups
Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.
First-Line Olaparib/Abiraterone Shows Clinical Benefit in BRCA+ mCRPC
Olaparib plus abiraterone improved radiographic PFS and overall survival in mCRPC patients with germline or somatic BRCA mutations vs placebo plus abiraterone.
Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
The hood technique, developed by Ash Tewari, MD, aids in facilitating earlier returns of continence with reduced residual cancer rates.
Fish Oil and a High Omega-3 Diet Reduced Prostate Ki-67 Index
Patients who did not receive fish oil experienced a Ki-67 index increase of 24% vs the 15% Ki-67 index decrease for patients with a low omega-6, high omega-3 diet who received fish oil.
Darolutamide/ADT Improves Outcomes in mHSPC Across Disease Volumes
The ARANOTE phase 3 trial showed darolutamide plus ADT improved outcomes in mHSPC regardless of disease volume.
Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS Regimen
Phase 3 ARASENS trial results highlight the role of G-CSF in optimizing docetaxel delivery within the darolutamide-based regimen for mHSPC.
EBRT Regimens Elicit 15-Year Prostate Cancer Survival Outcomes
More adverse factors occurred in those with intermediate-risk prostate cancer undergoing neoadjuvant androgen deprivation therapy than those who did not.
Talazoparib and Enzalutamide Improve Outcomes in Advanced Prostate Cancer
The TALAPRO-2 trial revealed promising survival data for patients with metastatic CRPC treated with talazoparib and enzalutamide.
Fast Track Designation Given to Novel PET Imaging Agent in Prostate Cancer
The imaging agent led to changes in intended treatment plans for 48% of patients with prostate cancer and biochemical recurrence after definitive therapy.
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.
VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.
FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.
Pembrolizumab/Cisplatin Combo Shows Promise in Small Cell Bladder Cancer, Neuroendocrine Prostate Cancer
Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.
SBRT Emerges as Viable Treatment for Localized Prostate Cancer
Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.
The Evolving Landscape of Prostate Cancer Management
Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.
Darolutamide/ADT Improves rPFS in Metastatic HSPC
Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC
Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC
Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer
Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
Novel PET Imaging Agent Earns Fast Track Status for PSMA+ Prostate Cancer
In 2 clinical trials, 64Cu-SAR-bisPSMA was shown to be effective in detecting prostate cancer in patients with PSMA-positive lesions.
IMRT Yields Similar QOL Vs Proton Therapy in Localized Prostate Cancer
Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.
Developers Submit Supplemental NDA for Darolutamide/ADT in mHSPC
Results from the ARANOTE trial support the supplemental new drug application for darolutamide/ADT in metastatic hormone-sensitive prostate cancer.
rPFS/OS Benefit in Radium-223 Plus Enzalutamide in mCRPC
Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.